Researchers at UCSF, Dublin City University and Ulster University have received approximately $9 million in combined funding
A formidable international research collaboration spanning three nations is taking aim at an exceptionally consequential challenge in pediatric medicine: altering the course of a rare inherited kidney disease before irreversible kidney failure occurs.
Researchers at UCSF, Dublin City University and Ulster University have secured approximately $9 million in combined research funding to accelerate the development of a novel therapeutic compound designed to intervene in a devastating kidney disorder that emerges in childhood and, for affected children, inexorably progresses toward kidney failure.
The transatlantic initiative brings together Minnie Sarwal, MD, PhD, of UCSF; Tia Keyes, PhD, of Dublin City University; and Bridgeen Callan, PhD, of Ulster University in an ambitious scientific enterprise spanning the United States, Republic of Ireland and Northern Ireland. Their collective expertise creates a multidisciplinary framework for translating fundamental molecular discovery into a potential therapeutic intervention.
[QUOTE FROM DR. MINNIE SARWAL — Suggested focus: the significance of the disease, what her laboratory discovered, and why this collaboration creates an unusual opportunity to intervene earlier.]
At the scientific foundation of the project are discoveries from Sarwal’s UCSF research team that have illuminated critical molecular pathways implicated in the progressive kidney damage associated with the disease. Those insights have opened a compelling therapeutic avenue: rather than managing the consequences of declining kidney function, the investigators are pursuing a compound engineered to disrupt the biological mechanisms driving the damage itself.
The international consortium will now advance that compound through the next phase of development, refining its formulation and evaluating its potential to preserve kidney function before irreversible injury takes hold. The work represents a pivotal transition from molecular insight toward therapeutic possibility, with the ultimate objective of moving a promising intervention closer to clinical development.
The scale and structure of the collaboration are equally distinctive. Supported through an uncommon three-nation funding mechanism, the approximately $9 million investment aligns complementary scientific capabilities across three institutions and three funding systems around a unified research program. That international architecture enables each team to contribute specialized expertise while pursuing a shared therapeutic objective.
[QUOTE FROM DR. TIA KEYES OR DR. BRIDGEEN CALLAN — Suggested focus: the power of the international partnership, complementary expertise across the three laboratories, and what becomes possible through the coordinated funding structure.]
For children and families confronting this disorder, the implications are profound. The prevailing trajectory has long been devastatingly predictable: progressive kidney injury beginning early in life and ultimately culminating in kidney failure. This collaboration is predicated on a markedly different possibility — that sufficiently early and precise intervention could alter that trajectory altogether. What begins as an international scientific endeavor therefore carries a singular and urgent ambition: to reach the disease before irreversible kidney failure does.
With substantial investment, convergent expertise and a promising therapeutic strategy now aligned across three nations, the consortium is positioned to test whether years of molecular discovery can be transformed into something considerably more consequential: a fundamentally different future for children born with this disease.